logo
China imposes exit bans on U.S. Department of Commerce employee and a Wells Fargo banker

China imposes exit bans on U.S. Department of Commerce employee and a Wells Fargo banker

CBS News6 days ago
A U.S. Department of Commerce employee has been restricted from leaving China by authorities in Beijing, a State Department spokesperson told CBS News on Monday. The unidentified government employee's restricted travel was confirmed as Beijing revealed new information about a U.S.-based Wells Fargo banker who has also been subjected to an exit ban.
"We can confirm that a U.S. Patent and Trademark Office employee, while traveling to China in a personal capacity, was made subject to an exit ban in China," the State Department spokesperson said Monday. "We are tracking this case very closely and are engaged with Chinese officials to resolve the situation as quickly as possible."
The New York Times reported Monday that the employee in question is a U.S. citizen who has been prevented from leaving China since mid-April. The newspaper cited a State Department document it has obtained, adding that it shows Beijing officials seized the man's passport, credit card, cellphone and iPad while he was in the city of Chengdu on April 14.
The Times said, citing the document, that the man's documents were returned on April 22, but that he was told he could not leave the country.
At a news conference on Monday, a Chinese Foreign Ministry spokesperson declined to comment on the case of the Department of Commerce employee beyond saying that Beijing "upholds the rule of law and handles entry and exit affairs in accordance with the law."
But Foreign Ministry spokesperson Guo Jiaku did confirm that Wells Fargo banker Mao Chenyue has been restricted from leaving China and is facing criminal charges.
"Ms. Mao Chenyue is involved in a criminal case currently being handled by Chinese law-enforcement authorities and is subjected to exit restrictions in accordance with the law. Pursuant to Chinese laws, with the case still under investigation, Ms. Mao cannot leave the country for the time being and has an obligation to cooperate with the investigation," Chinese Foreign Ministry spokesperson Guo Jiaku said Monday.
Chenyue is a Managing Director at Wells Fargo and is based in Atlanta, according to her Linkedin profile. Her Linkedin account also says she is bilingual in English and Chinese.
Mao leads Wells Fargo's international factoring business and was born in Shanghai, according to a June press release on the website of the non profit FCI, a global network of companies that provides factoring services.
It was not clear on Tuesday whether Mao holds dual Chinese and U.S. nationality.
A Wells Fargo representative told CBS News in a statement on Monday that the company was "closely tracking this situation and working through the appropriate channels so our employee can return to the United States as soon as possible."
A U.S. State Department spokesperson declined to comment Monday on Chenyue's status, "due to privacy and other considerations," but said the State Department "has no higher priority than the safety and security of American citizens."
On its website, the State Department urges Americans travelling in China to "exercise increased caution," warning that China "arbitrarily enforces local laws, including exit bans on U.S. citizens and citizens of other countries, without fair and transparent process under the law."
U.S. citizens may only realize they have been subjected to an exit ban when they attempt to leave China, and there may be no available legal recourse to appeal such a ban via a Chinese court, according to the State Department's travel advisory.
The Chinese government also does not recognize dual nationality, meaning "U.S. citizens of Chinese descent may be subject to additional scrutiny and harassment," the guidance on the State Department's website says.
The latest incidents come at a sensitive time in relations between Beijing and Washington. In late June, the White House and officials in Beijing said the two sides had agreed on the framework of a new deal to end a trade war between the world's two largest economies.
As it stands, China faces an August 12 deadline — imposed by President Trump — to strike a new trade deal with the U.S. to end an escalating tit-for-tat trade tariff war that the countries have engaged in since Mr. Trump returned to the White House in January.
Mr. Trump imposed tariffs of up to 145% on imports from China, and Beijing responded with its own steep import duties, but the two sides agreed to a truce to allow for negotiations. In the meantime, the Trump administration has imposed 30% tariffs on imports from China, pending the August 12 deadline, when much higher rates will be imposed by both Washington and Beijing if no agreement is reached.
The standoff has increased the risks for American companies doing business in China that had already been mounting for several years.
In June 2023, after Chinese authorities raided the offices of several U.S.-based firms, Beijing-based business lawyer James Zimmerman told CBS News it seemed everything was being taken by the Communist Party as a potential threat.
"Unfortunately, in that kind of environment it's very difficult to operate — when everything is viewed as a national security matter and… it looks as if…. anything you do could be considered to be spying," he said.Olivia Victoria Gazis
contributed to this report.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ceconomy enters talks with China's JD.com for potential takeover
Ceconomy enters talks with China's JD.com for potential takeover

Yahoo

time13 minutes ago

  • Yahoo

Ceconomy enters talks with China's JD.com for potential takeover

German electronics retailer Ceconomy, which operates MediaMarkt and Saturn brands, is engaged in advanced talks with Chinese e-commerce company over a possible voluntary public takeover. is contemplating a cash offer of €4.60 per ordinary share, compliant with the German Securities Acquisition and Takeover Act, according to Ceconomy's statement of 24 July 2025. No binding agreements have yet been reached, and it remains uncertain whether a formal takeover offer will proceed. The Chinese company disclosed its interest in a potential deal towards the end of 2023. Reuters reports that a proposed transaction could value the company at approximately €2.2bn ($2.59bn). Ceconomy's largest shareholder is the Kellerhals family, while the Haniel family owns 17%. Meridian, Beisheim and Freenet hold smaller stakes. 36.3% of Ceconomy's shares are freely traded. MediaMarkt and Saturn manage 1,030 stores across multiple European countries and employ 50,000 staff, as of 30 September 2024. The brands also operate a major online electronics retail platform. In the 2023/24 financial year, Ceconomy recorded total sales of €22.4bn, of which €5.1bn were online. According to Bloomberg, logistics division's delivery network could enhance the operations of Ceconomy's physical retail outlets. In the first quarter of 2025, reported net revenues of $41.5bn and net income attributable to the company's ordinary shareholders of $1.5bn. The Chinese company launched an export-to-domestic sales programme in April, 2025, with plans 'to procure no less than 200bn yuan worth of export-oriented goods for domestic sales'. In August 2024, Walmart sold its stake in to raise $3.74bn, a term sheet seen by Reuters has revealed. The decision was part of the US retailer's strategy to focus on its own operations within China. Walmart sold 144.5 million American depositary shares priced between $24.85 and $25.85. "Ceconomy enters talks with China's for potential takeover" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Cheetah Mobile to Acquire Controlling Stake in UFACTORY to Accelerate Its Robotics Commercialization Strategy
Cheetah Mobile to Acquire Controlling Stake in UFACTORY to Accelerate Its Robotics Commercialization Strategy

Yahoo

time13 minutes ago

  • Yahoo

Cheetah Mobile to Acquire Controlling Stake in UFACTORY to Accelerate Its Robotics Commercialization Strategy

BEIJING, July 28, 2025 /PRNewswire/ -- Cheetah Mobile Inc. (NYSE: CMCM) ("Cheetah Mobile" or the "Company"), a China-based IT company, today announced that one of its majority-owned subsidiaries has signed a definitive agreement to acquire an equity interest of 60.8% in Shenzhen UFACTORY Technology Co., Ltd. ("UFACTORY"), a leading provider of lightweight robotic arms, for a total consideration of approximately RMB99.5 million. Prior to the transaction, another wholly-owned subsidiary of Cheetah Mobile already held 19.2% of UFACTORY's total equity interest. Following the transaction, the two subsidiaries will collectively hold approximately 80.0% of UFACTORY's total equity interest, representing Cheetah Mobile's ultimate beneficial ownership in UFACTORY of approximately 75.8%. The transaction has been approved by the Company's board of directors and audit committee and is expected to close in the third quarter of 2025, subject to customary closing conditions. Mr. Sheng Fu, Cheetah Mobile's Chairman and Chief Executive Officer, commented, "We're excited to deepen our investment in UFACTORY, a fast-growing leader in collaborative robotics. With its robust technology stack and lean go-to-market approach, UFACTORY is an ideal partner to support our next stage of growth in AI and robotics. With this acquisition, we're strengthening our product portfolio to help our service robots operate across more physical environments and tasks. This marks a significant step forward in our mission to deliver smarter, more adaptable robotics solutions to global markets." Mr. Thomas Ren, Cheetah Mobile's Director and Chief Financial Officer, commented: "We will fund the acquisition with our cash reserves. As of March 31, 2025, we held over USD230 million in net cash, giving us ample flexibility to pursue strategic investments that have the potential to deliver sustainable shareholder value." About UFACTORY UFACTORY is a leading provider of lightweight collaborative robotic arms - designed to safely work alongside humans in shared environments. Under the brand "UFACTORY xArm", the company is one of the few robotic arm providers generating net profits and substantial revenue from overseas markets, having achieved sustained growth over the past years. Backed by proprietary full-stack robotics technologies, UFACTORY offers a diverse portfolio of five-, six-, and seven-axis robotic arms and robotic accessories. UFACTORY's developer-friendly design makes its robotic arms and accessories highly adaptable across different use cases, empowering customers with flexibility and ease of deployment. UFACTORY has built a loyal, global customer base with increasing revenues from international markets. About Cheetah Mobile Inc. Cheetah Mobile is a China-based IT company with a commitment to AI innovation. It has attracted hundreds of millions of users through an array of internet products and services on PCs and mobile devices. At the same time, it actively engages in the independent research and development of AI technologies, including LLM technologies. Cheetah Mobile provides advertising services to advertisers worldwide, value-added services including the sale of premium membership to its users, multi-cloud management platform to companies globally, as well as service robots to international clients. Cheetah Mobile is also committed to leveraging its cutting-edge AI technologies, including LLM technologies, to empower its products and make the world smarter. It has been listed on the New York Stock Exchange since May 2014. Safe Harbor Statement This press release contains forward-looking statements. These statements, including management quotes and business outlook, constitute forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Such statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in the forward-looking statements, including but are not limited to the following: Cheetah Mobile's growth strategies; Cheetah Mobile's ability to retain and increase its user base and expand its product and service offerings; Cheetah Mobile's ability to monetize its platform; Cheetah Mobile's future business development, financial condition and results of operations; competition with companies in a number of industries including internet companies that provide online marketing services and internet value-added services; expected changes in Cheetah Mobile's revenues and certain cost or expense items; and general economic and business condition globally and in China. Further information regarding these and other risks is included in Cheetah Mobile's filings with the U.S. Securities and Exchange Commission. Cheetah Mobile does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. Investor Relations Contact Helen Jing ZhuCheetah Mobile +86 10 6292 7779Email: ir@ View original content: SOURCE Cheetah Mobile Melden Sie sich an, um Ihr Portfolio aufzurufen.

Hengrui Pharma and GSK link across key therapeutic areas
Hengrui Pharma and GSK link across key therapeutic areas

Yahoo

time13 minutes ago

  • Yahoo

Hengrui Pharma and GSK link across key therapeutic areas

Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic areas, including respiratory, immunology and inflammation, and oncology. The collaboration is poised to enhance Hengrui's globalisation strategy and provide GSK with significant growth opportunities beyond 2031. GSK will pay an upfront fee of $500m, which includes licensing for the phosphodiesterase (PDE)3/4 programme. The potential value of future success-based payments to Hengrui Pharma could be close to $12bn, assuming all programmes are optioned and milestones met. Hengrui Pharma is also set to receive tiered royalties on worldwide product net sales, with certain regional exclusions. A highlight of the agreement is the worldwide licence for HRS-9821, a PDE3/4 inhibitor in clinical development for chronic obstructive pulmonary disease (COPD). HRS-9821 aligns with GSK's goal to address a broad spectrum of COPD patients, including those with ongoing dyspnoea or those less likely to be prescribed inhaled corticosteroids or biologics. In early trials, this inhibitor showed positive anti-inflammatory and bronchodilation effects. Its potential for a dry-powder inhaler formulation could integrate well with GSK's existing inhaled portfolio. Hengrui Pharma executive vice-president and chief strategy officer Frank Jiang stated: 'GSK brings additional research and development expertise, a robust global clinical network and broad regulatory capabilities that will accelerate our PDE3/4 inhibitor as well as an array of other innovative therapy programmes to overseas markets, potentially delivering breakthrough treatments to patients globally." Beyond HRS-9821, the collaboration includes up to 11 additional programmes. Hengrui Pharma will spearhead the development up to Phase I trials, after which GSK may opt to develop further and commercialise the programmes globally, excluding mainland China, the Macau special administrative region (SAR), Hong Kong SAR and Taiwan. This scaled collaboration is designed to expedite the development of innovative medicines, leveraging GSK's expertise and global reach alongside Hengrui Pharma's discovery and clinical evaluation capabilities. The licensing of HRS-9821 is contingent upon customary regulatory clearances, including under the Hart-Scott-Rodino Act in the US. In March 2025, MSD entered an exclusive licence agreement with Hengrui Pharma for the investigational oral small-molecule lipoprotein(a) [Lp(a)] inhibitor, HRS-5346. "Hengrui Pharma and GSK link across key therapeutic areas" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store